Journal Article

Reversal of Human Immunodeficiency Virus Type 1-Associated Hematosuppression by Effective Antiretroviral Therapy

Susan S. Huang, Jason D. Barbour, Steven G. Deeks, Jeannie S. Huang, Robert M. Grant, Valerie L. Ng and Joseph M. McCune

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 30, issue 3, pages 504-510
Published in print March 2000 | ISSN: 1058-4838
Published online March 2000 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/313714
Reversal of Human Immunodeficiency Virus Type 1-Associated Hematosuppression by Effective Antiretroviral Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The immunodeficiency of human immunodeficiency virus type 1 (HIV-1) disease may be due to accelerated destruction of mature CD4+ T cells and/or impaired differentiation of progenitors of CD4+ T cells. HIV-1 infection may also inhibit the production of other hematopoietic lineages, by directly or indirectly suppressing the maturation of multilineage and/or lineage-restricted hematopoietic progenitor cells. To test this hypothesis, the effects of durable viral suppression on multilineage hematopoiesis in 66 HIV-1-seropositive patients were evaluated. Administration of effective antiretroviral therapy resulted in an increase in circulating CD4+ T cell counts and statistically significant increases in circulating levels of other hematopoietic lineages, including total white blood cells, lymphocytes, polymorphonuclear leukocytes, and platelets. These results suggest that a significant lesion in untreated HIV-1 disease may lie at the level of cell production from hematopoietic progenitors.

Journal Article.  4436 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.